UnitedHealth Group, the largest health insurer in the United States, stated on Tuesday that while Medicare is set to cover obesity medications for the first time, the program's implementation faces significant challenges, leading the company to maintain a cautious outlook regarding its near-term financial impact.
Executives from UnitedHealth indicated during an investor conference that starting April 1, 2026, Medicare beneficiaries will be able to access GLP-1 class obesity drugs such as Eli Lilly's Zepbound and oral medication orforglipron for a monthly out-of-pocket cost not exceeding $50. However, uncertainties remain regarding the practical execution of this policy. UnitedHealth anticipates that the new coverage policy could result in substantial pharmacy cost pressures for its Medicare Advantage plans in the second half of 2026, with the exact scale depending on the actual number of users and specific drug pricing details.
The company highlighted two primary "challenges": first, high demand for GLP-1 medications may lead to enrollment numbers exceeding expectations; second, there is a need to ensure the clinical appropriateness of prescriptions to prevent medication misuse.
Concurrently, UnitedHealth is adjusting the design of its 2026 Medicare Advantage plans. Some prescription drug tiers have been modified to incorporate coinsurance based on a percentage rather than fixed copayments, as a measure to manage potential fluctuations in drug expenditures. These adjustments are viewed as proactive steps to control financial risks.
Despite expecting short-term difficulties, UnitedHealth remains optimistic about the long-term value of obesity management, asserting that scientifically guided medication use combined with lifestyle interventions can help reduce overall healthcare spending. The company will continue to monitor related policy developments and collaborate with regulators to ensure the program's sustainability.
Comments